{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:51:11Z","timestamp":1790095871380,"version":"4.0.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T00:00:00Z","timestamp":1735776000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>There is insufficient evidence comparing the outcomes of tacrolimus-based remission induction therapy with infliximab in refractory ulcerative colitis (UC) and evidence regarding optimal strategies after tacrolimus-based remission induction therapy. We conducted a multi-institutional retrospective study of patients with UC treated with tacrolimus or infliximab between January 2010 and March 2019. The proportion of clinical remission at week 8 and cumulative colectomy-free rate were examined using propensity score matching analysis. The predictors for colectomy after tacrolimus induction were also investigated. Ninety patients in the tacrolimus group and 151 in the infliximab group were enrolled. The proportion of patients in clinical remission at week 8 was 65.2% in the matched tacrolimus group and 37.3% in the matched infliximab group (P\u2009=\u20090.0016), and the long-term colectomy-free rate was lower in the matched tacrolimus group than in the matched infliximab group (P\u2009=\u20090.0003). After clinical remission with tacrolimus, a serum albumin level of\u2009\u2264\u20093.5\u00a0g\/dL at week 8 was extracted as a factor predicting colectomy (area under the curve: 0.94). Tacrolimus showed a higher remission induction effect for UC compared to infliximab. However, a high rate of colectomy after transition to maintenance treatment was found to be a concern for tacrolimus therapy.<\/jats:p>","DOI":"10.1038\/s41598-024-77365-y","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T02:34:58Z","timestamp":1735871698000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness of tacrolimus therapy in refractory ulcerative colitis compared to infliximab with propensity score matching"],"prefix":"10.1038","volume":"15","author":[{"given":"Takeo","family":"Yoshihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Amano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichiro","family":"Shinzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri","family":"Tsujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Asakura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taku","family":"Tashiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Tani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuriko","family":"Otake-Kasamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Sakakibara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Osugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Egawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Arimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masanori","family":"Nakahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoko","family":"Murayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichizo","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Kinoshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Hiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narihiro","family":"Shibukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yorihide","family":"Okuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuhisa","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiki","family":"Tsujii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Iijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuo","family":"Takehara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,2]]},"reference":[{"key":"77365_CR1","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1093\/ibd\/izab202","volume":"28","author":"B Saberzadeh-Ardestani","year":"2022","unstructured":"Saberzadeh-Ardestani, B. et al. Clinical phenotype and disease course of inflammatory bowel disease: a comparison between sporadic and familial cases. Inflamm. Bowel Dis. 28, 1004\u20131011. https:\/\/doi.org\/10.1093\/ibd\/izab202 (2022).","journal-title":"Inflamm. Bowel Dis."},{"key":"77365_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/apt.16445","volume":"54","author":"RCA van Linschoten","year":"2021","unstructured":"van Linschoten, R. C. A. et al. Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents. Aliment Pharmacol. Ther. 54, 234\u2013248. https:\/\/doi.org\/10.1111\/apt.16445 (2021).","journal-title":"Aliment Pharmacol. Ther."},{"key":"77365_CR3","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.cgh.2017.06.016","volume":"16","author":"M Fumery","year":"2018","unstructured":"Fumery, M. et al. Natural history of adult ulcerative colitis in population-based cohorts: a systematic review. Clin. Gastroenterol. Hepatol. 16, 343\u2013356.e343. https:\/\/doi.org\/10.1016\/j.cgh.2017.06.016 (2018).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"77365_CR4","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1111\/apt.17145","volume":"56","author":"M Zhao","year":"2022","unstructured":"Zhao, M. et al. Therapeutic management and outcomes in inflammatory bowel diseases, 2010 to 2017 in cohorts from Denmark, Sweden and Norway. Aliment Pharmacol. Ther. 56, 989\u20131006. https:\/\/doi.org\/10.1111\/apt.17145 (2022).","journal-title":"Aliment Pharmacol. Ther."},{"key":"77365_CR5","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1007\/s00535-023-02048-w","volume":"58","author":"M Naganuma","year":"2023","unstructured":"Naganuma, M. et al. Real-world efficacy and safety of advanced therapies in hospitalized patients with ulcerative colitis. J. Gastroenterol. 58, 1198\u20131210. https:\/\/doi.org\/10.1007\/s00535-023-02048-w (2023).","journal-title":"J. Gastroenterol."},{"key":"77365_CR6","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1093\/ibd\/izy383","volume":"25","author":"MC Choy","year":"2019","unstructured":"Choy, M. C. et al. Systematic review and meta-analysis: optimal salvage therapy in acute severe ulcerative colitis. Inflamm. Bowel Dis. 25, 1169\u20131186. https:\/\/doi.org\/10.1093\/ibd\/izy383 (2019).","journal-title":"Inflamm. Bowel Dis."},{"key":"77365_CR7","doi-asserted-by":"publisher","first-page":"3162595","DOI":"10.1155\/2016\/3162595","volume":"2016","author":"K Endo","year":"2016","unstructured":"Endo, K. et al. A comparison of short- and long-term therapeutic outcomes of infliximab- versus tacrolimus-based strategies for steroid-refractory ulcerative colitis. Gastroenterol. Res. Pract. 2016, 3162595. https:\/\/doi.org\/10.1155\/2016\/3162595 (2016).","journal-title":"Gastroenterol. Res. Pract."},{"key":"77365_CR8","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","volume":"330","author":"S Lichtiger","year":"1994","unstructured":"Lichtiger, S. et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N. Engl. J. Med. 330, 1841\u20131845. https:\/\/doi.org\/10.1056\/NEJM199406303302601 (1994).","journal-title":"N. Engl. J. Med."},{"key":"77365_CR9","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/ibd.21853","volume":"18","author":"H Ogata","year":"2012","unstructured":"Ogata, H. et al. Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis. Inflamm. Bowel Dis. 18, 803\u2013808. https:\/\/doi.org\/10.1002\/ibd.21853 (2012).","journal-title":"Inflamm. Bowel Dis."},{"key":"77365_CR10","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1093\/ecco-jcc\/jjad004","volume":"17","author":"JP Gisbert","year":"2023","unstructured":"Gisbert, J. P., Garc\u00eda, M. J. & Chaparro, M. Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review. J. Crohns Colitis 17, 972\u2013994. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad004 (2023).","journal-title":"J. Crohns Colitis"},{"key":"77365_CR11","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1093\/ecco-jcc\/jjv221","volume":"10","author":"Y Komaki","year":"2016","unstructured":"Komaki, Y., Komaki, F., Ido, A. & Sakuraba, A. Efficacy and safety of tacrolimus therapy for active ulcerative colitis; a systematic review and meta-analysis. J. Crohns Colitis 10, 484\u2013494. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjv221 (2016).","journal-title":"J. Crohns Colitis"},{"key":"77365_CR12","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s00535-010-0352-z","volume":"46","author":"M Naganuma","year":"2011","unstructured":"Naganuma, M., Fujii, T. & Watanabe, M. The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease. J. Gastroenterol. 46, 129\u2013137. https:\/\/doi.org\/10.1007\/s00535-010-0352-z (2011).","journal-title":"J. Gastroenterol."},{"key":"77365_CR13","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","volume":"56","author":"H Nakase","year":"2021","unstructured":"Nakase, H. et al. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J. Gastroenterol. 56, 489\u2013526. https:\/\/doi.org\/10.1007\/s00535-021-01784-1 (2021).","journal-title":"J. Gastroenterol."},{"key":"77365_CR14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s00535-018-1439-1","volume":"53","author":"K Matsuoka","year":"2018","unstructured":"Matsuoka, K. et al. Evidence-based clinical practice guidelines for inflammatory bowel disease. J. Gastroenterol. 53, 305\u2013353. https:\/\/doi.org\/10.1007\/s00535-018-1439-1 (2018).","journal-title":"J. Gastroenterol."},{"key":"77365_CR15","doi-asserted-by":"publisher","unstructured":"Yamamoto, T., Shimoyama, T., Umegae, S. & Matsumoto, K. Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. Aliment Pharmacol. Ther. 43, 705\u2013716. https:\/\/doi.org\/10.1111\/apt.13531 (2016).","DOI":"10.1111\/apt.13531"},{"key":"77365_CR16","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(12)61084-8","volume":"380","author":"D Laharie","year":"2012","unstructured":"Laharie, D. et al. Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet 380, 1909\u20131915. https:\/\/doi.org\/10.1016\/S0140-6736(12)61084-8 (2012).","journal-title":"Lancet"},{"key":"77365_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S2468-1253(16)30003-6","volume":"1","author":"JG Williams","year":"2016","unstructured":"Williams, J. G. et al. Infliximab versus ciclosporin for steroid-resistant acute severe ulcerative colitis (CONSTRUCT): a mixed methods, open-label, pragmatic randomised trial. Lancet Gastroenterol. Hepatol. 1, 15\u201324. https:\/\/doi.org\/10.1016\/S2468-1253(16)30003-6 (2016).","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"77365_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1093\/ecco-jcc\/jjaa226","volume":"15","author":"B Barberio","year":"2021","unstructured":"Barberio, B., Black, C. J., Savarino, E. V. & Ford, A. C. Ciclosporin or infliximab as rescue therapy in acute glucorticosteroid-refractory ulcerative colitis: systematic review and network meta-analysis. J. Crohns Colitis 15, 733\u2013741. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjaa226 (2021).","journal-title":"J. Crohns Colitis"},{"key":"77365_CR19","doi-asserted-by":"publisher","unstructured":"Jia, X. et al. Efficacy of infliximab, cyclosporine and tacrolimus on ulcerative colitis: a meta-analysis. Med. (Baltim.) 99, e22894. https:\/\/doi.org\/10.1097\/MD.0000000000022894 (2020).","DOI":"10.1097\/MD.0000000000022894"},{"key":"77365_CR20","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3109\/00365521.2016.1138239","volume":"51","author":"Y Nuki","year":"2016","unstructured":"Nuki, Y. et al. Comparison of the therapeutic efficacy and safety between tacrolimus and infliximab for moderate-to-severe ulcerative colitis: a single center experience. Scand. J. Gastroenterol. 51, 700\u2013705. https:\/\/doi.org\/10.3109\/00365521.2016.1138239 (2016).","journal-title":"Scand. J. Gastroenterol."},{"key":"77365_CR21","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000481815","volume":"36","author":"K Takeuchi","year":"2018","unstructured":"Takeuchi, K., Shimoyama, T. & Yamamoto, T. Comparison of safety and efficacy of tacrolimus versus infliximab for active ulcerative colitis. Dig. Dis. 36, 106\u2013112. https:\/\/doi.org\/10.1159\/000481815 (2018).","journal-title":"Dig. Dis."},{"key":"77365_CR22","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1515\/rjim-2017-0012","volume":"55","author":"H Yamagami","year":"2017","unstructured":"Yamagami, H. et al. A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis. Rom J. Intern. Med. 55, 151\u2013157. https:\/\/doi.org\/10.1515\/rjim-2017-0012 (2017).","journal-title":"Rom J. Intern. Med."},{"key":"77365_CR23","doi-asserted-by":"publisher","first-page":"e000021","DOI":"10.1136\/bmjgast-2014-000021","volume":"2","author":"N Minami","year":"2015","unstructured":"Minami, N. et al. Tacrolimus or infliximab for severe ulcerative colitis: short-term and long-term data from a retrospective observational study. BMJ Open Gastroenterol. 2, e000021. https:\/\/doi.org\/10.1136\/bmjgast-2014-000021 (2015).","journal-title":"BMJ Open Gastroenterol."},{"key":"77365_CR24","first-page":"E140","volume":"64","author":"T Otsuka","year":"2018","unstructured":"Otsuka, T. et al. Short-term and long-term outcomes of infliximab and tacrolimus treatment for moderate to severe ulcerative colitis: retrospective observational study. Kobe J. Med. Sci. 64, E140\u2013E148 (2018).","journal-title":"Kobe J. Med. Sci."},{"key":"77365_CR25","doi-asserted-by":"publisher","unstructured":"Liu, Y. J. et al. Pooled analysis of the comparative efficacy between tacrolimus and infliximab for ulcerative colitis. Med. (Baltim.) 97, e11440. https:\/\/doi.org\/10.1097\/MD.0000000000011440 (2018).","DOI":"10.1097\/MD.0000000000011440"},{"key":"77365_CR26","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/jgh3.12140","volume":"3","author":"T Suzuki","year":"2019","unstructured":"Suzuki, T. et al. The efficacy of maintenance therapy after remission induction with tacrolimus in ulcerative colitis with and without previous tumor necrosis factor-\u03b1 inhibitor. JGH Open 3, 217\u2013223. https:\/\/doi.org\/10.1002\/jgh3.12140 (2019).","journal-title":"JGH Open"},{"key":"77365_CR27","doi-asserted-by":"publisher","first-page":"13572","DOI":"10.1038\/s41598-022-17763-2","volume":"12","author":"N Ishida","year":"2022","unstructured":"Ishida, N. et al. Lymphocyte to monocyte ratio and serum albumin changes predict tacrolimus therapy outcomes in patients with ulcerative colitis. Sci. Rep. 12, 13572. https:\/\/doi.org\/10.1038\/s41598-022-17763-2 (2022).","journal-title":"Sci. Rep."},{"key":"77365_CR28","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.16006","author":"N Takatsu","year":"2022","unstructured":"Takatsu, N. et al. Thiopurine naivety at tacrolimus induction is a predictor of long-term remission in patients with intractable ulcerative colitis who responded to tacrolimus. J. Gastroenterol. Hepatol. https:\/\/doi.org\/10.1111\/jgh.16006 (2022).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"77365_CR29","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad106","author":"J Burisch","year":"2023","unstructured":"Burisch, J., Safroneeva, E., Laoun, R. & Ma, C. Lack of benefit for early escalation to advanced therapies in ulcerative colitis: critical appraisal of current evidence. J. Crohns Colitis https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad106 (2023).","journal-title":"J. Crohns Colitis"},{"key":"77365_CR30","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1093\/ecco-jcc\/jjad022","volume":"17","author":"M L\u00f6wenberg","year":"2023","unstructured":"L\u00f6wenberg, M. et al. Mercaptopurine for the treatment of ulcerative colitis: a randomized placebo-controlled trial. J. Crohns Colitis 17, 1055\u20131065. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjad022 (2023).","journal-title":"J. Crohns Colitis"},{"key":"77365_CR31","doi-asserted-by":"publisher","unstructured":"Wang, X. et al. Network meta-analysis and cost-effectiveness analysis of infliximab, cyclosporine and tacrolimus for ulcerative colitis. Med. (Baltim.) 101, e31850. https:\/\/doi.org\/10.1097\/MD.0000000000031850 (2022).","DOI":"10.1097\/MD.0000000000031850"},{"key":"77365_CR32","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1093\/ecco-jcc\/jjab029","volume":"15","author":"M Zhao","year":"2021","unstructured":"Zhao, M., G\u00f6nczi, L., Lakatos, P. L. & Burisch, J. The Burden of inflammatory bowel disease in Europe in 2020. J. Crohns Colitis 15, 1573\u20131587. https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab029 (2021).","journal-title":"J. Crohns Colitis"},{"key":"77365_CR33","doi-asserted-by":"publisher","unstructured":"Schroeder, K. W., Tremaine, W. J. & Ilstrup, D. M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N. Engl. J. Med. 317, 1625\u20131629. https:\/\/doi.org\/10.1056\/NEJM198712243172603 (1987).","DOI":"10.1056\/NEJM198712243172603"},{"key":"77365_CR34","doi-asserted-by":"publisher","unstructured":"Mentella, M. C., Scaldaferri, F., Pizzoferrato, M., Gasbarrini, A. & Miggiano, G. A. D. The association of disease activity, BMI and phase angle with vitamin D deficiency in patients with IBD. Nutrients 11, 456. https:\/\/doi.org\/10.3390\/nu11112583 (2019).","DOI":"10.3390\/nu11112583"},{"key":"77365_CR35","doi-asserted-by":"publisher","unstructured":"Stuart, E. A., Lee, B. K. & Leacy, F. P. Prognostic score-based balance measures can be a useful diagnostic for propensity score methods in comparative effectiveness research. J. Clin. Epidemiol. 66, S84-S90.e81. https:\/\/doi.org\/10.1016\/j.jclinepi.2013.01.013 (2013).","DOI":"10.1016\/j.jclinepi.2013.01.013"},{"key":"77365_CR36","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1023\/A:1020363010465","volume":"2","author":"DB Rubin","year":"2001","unstructured":"Rubin, D. B. Using propensity scores to help design observational studies: application to the tobacco litigation. Health Serv. Outcomes Res. Methodol. 2, 169\u2013188. https:\/\/doi.org\/10.1023\/A:1020363010465 (2001).","journal-title":"Health Serv. Outcomes Res. Methodol."},{"key":"77365_CR37","doi-asserted-by":"crossref","unstructured":"Akaike, H. In Selected Papers of Hirotugu Akaike (eds. Emanuel, P. et al.) 199\u2013213 (Springer New York, 1998).","DOI":"10.1007\/978-1-4612-1694-0_15"},{"key":"77365_CR38","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/B978-0-08-044894-7.01333-6","volume":"7","author":"A Maydeu-Olivares","year":"2010","unstructured":"Maydeu-Olivares, A. & Garcia-Forero, C. Goodness-of-fit testing. Int. Encycl. Educ. 7, 190\u2013196 (2010).","journal-title":"Int. Encycl. Educ."},{"key":"77365_CR39","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda, Y. Investigation of the freely available easy-to-use software \u201cEZR\u201d for medical statistics. Bone Marrow Transplant 48, 452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244 (2013).","journal-title":"Bone Marrow Transplant"},{"key":"77365_CR40","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.cgh.2018.08.081","volume":"17","author":"G Pellet","year":"2019","unstructured":"Pellet, G. et al. Efficacy and safety of induction therapy with calcineurin inhibitors in combination with vedolizumab in patients with refractory ulcerative colitis. Clin. Gastroenterol. Hepatol. 17, 494\u2013501. https:\/\/doi.org\/10.1016\/j.cgh.2018.08.081 (2019).","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"77365_CR41","doi-asserted-by":"publisher","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","volume":"114","author":"DT Rubin","year":"2019","unstructured":"Rubin, D. T., Ananthakrishnan, A. N., Siegel, C. A., Sauer, B. G. & Long, M. D. ACG clinical guideline: ulcerative colitis in adults. Am. J. Gastroenterol. 114, 384\u2013413. https:\/\/doi.org\/10.14309\/ajg.0000000000000152 (2019).","journal-title":"Am. J. Gastroenterol."},{"key":"77365_CR42","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1007\/s00535-021-01793-0","volume":"56","author":"S Shinzaki","year":"2021","unstructured":"Shinzaki, S. et al. Leucine-rich alpha-2 glycoprotein is a potential biomarker to monitor disease activity in inflammatory bowel disease receiving adalimumab: PLANET study. J. Gastroenterol. 56, 560\u2013569. https:\/\/doi.org\/10.1007\/s00535-021-01793-0 (2021).","journal-title":"J. Gastroenterol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77365-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77365-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77365-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T21:14:16Z","timestamp":1735938856000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-77365-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["77365"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-77365-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,2]]},"assertion":[{"value":"24 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Takeo Yoshihara received lecture fees from EA Pharma Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, and Nippon Kayaku Co., Ltd. Takahiro Amano received lecture fees from Janssen Pharmaceutical K.K. and Mitsubishi Tanabe Pharma Corporation. Shinichiro Shinzaki received personal fees from AbbVie Inc., EA Pharma Co., Ltd., Eisai Co., Ltd., Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Corporation, and Nippon Kayaku Co., Ltd., and scholarship grants from AbbVie Inc., EA Pharma Co., Ltd., and Nippon Kayaku Co., Ltd. Satoshi Egawa received lecture fees from Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutical K.K. Satoshi Hiyama1 received lecture fees from Mitsubishi Tanabe Pharma Corporation and AbbVie Inc. Hideki Iijima received lecture fees from AbbVie Inc., Janssen Pharmaceutical K.K., EA Pharma Co., Ltd., Eisai Pharmaceutical Co., Ltd., Mitsubishi Tanabe Pharma Corporation, and Mochida Pharmaceutical Co., Ltd. Yoshito Hayashi received lecture fees from EA Pharma Co., Ltd and Nippon Kayaku Co., Ltd. Tetsuo Takehara received lecture fees from AbbVie Inc.,consigned\/joint research expenses from AbbVie Inc., Janssen Pharmaceutical K.K., and Mitsubishi Tanabe Pharma Corporation, and scholarship donations from AbbVie Inc., EA Pharma Co., Ltd., Nippon Kayaku Co., Ltd. and Mitsubishi Tanabe Pharma Corporation. None of the disclosures mentioned above are related to this study. The remaining authors do not have any conflicts of interest to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by the Ethics Committee of Osaka University Hospital and by the Ethics Committees of the respective institutions (the ethics approval number: 18208).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The requirement for written informed consent was waived by allowing the participants to opt out because of the study\u2019s retrospective nature.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}}],"article-number":"68"}}